Short answer
Inhibikase Therapeutics, Inc. (IKT) filed an 8-K current report with the SEC on June 29, 2026 reporting Item 5.02 (Departure/Election of Directors or Officers), Item 5.07 (Submission of Matters to a Vote of Security Holders). 2026 Annual Meeting held June 26, 2026 via virtual-only webcast.
Inhibikase Therapeutics, Inc. 8-K event analysis
AI summary of each reported item and its exhibits
Item 5.02 · Departure/Election of Directors or Officers
- 2026 Annual Meeting held June 26, 2026 via virtual-only webcast
Item 5.07 · Submission of Matters to a Vote of Security Holders
- Arvind Kush and Dennis Berman elected as Class III directors through 2029, providing board continuity
- CohnReznick LLP ratified for fiscal 2026 auditing, with 106,910,712 votes for and 96,428 against
- Officer liability protection amendment approved, potentially reducing personal exposure for certain Delaware-law-permitted claims
- Equity plan expanded by 3,000,000 shares, increasing potential dilution capacity for employee and executive compensation
- Executive compensation approved; annual say-on-pay votes adopted, with 77,456,671 votes favoring one-year frequency
Generated from the filing text and exhibits; verify against the original. What 8-K item codes mean
Other Inhibikase Therapeutics, Inc. 8-K filings
Get the next IKT 8-K as it lands
Follow IKT for push alerts, or ask the research agent what this filing means.